AneurysmIntravenous abciximab for parent vessel thrombus during basilar apex aneurysm coil embolization: Case report and literature review☆
Section snippets
History
A 45-year-old man was found incidentally to have a basilar apex aneurysm while undergoing a magnetic resonance imaging study for evaluation of a minor head injury. The patient denied any history suggestive of subarachnoid hemorrhage, transient ischemic attack, or stroke. After a review of the surgical and endovascular options, the patient elected to have the aneurysm treated with coils.
Procedure
The angiogram and intervention were performed during the same procedure. Midazolam and fentanyl were
Discussion
The endovascular treatment of intracranial aneurysms has evolved dramatically over the past decade [5]. Thromboembolic events, though, remain a significant complication of this approach [21]. In a recent analysis of reported cases of aneurysm coiling since 1992, Qureshi et al identified thromboembolic complications in 127 (8.2%) of 1,547 patients [23]. The majority of these events occurred intraprocedurally and resulted in strokes in 86 patients. The outcomes for patients who experienced stroke
Acknowledgements
We thank Paul H. Dressel for preparation of the illustrations and the staff at Kaleida Gates Hospital Library for assistance in obtaining the reference articles.
References (32)
Abciximab in acute ischemic strokea randomized, double-blind, placebo-controlled, dose-escalation study
Stroke
(2000)- et al.
Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention
JAMA
(2001) - et al.
Management of intraprocedural arterial thrombus in cerebral aneurysm embolization with abciximabtechnical case report
Neurosurgery
(2002) Abciximab combined with angioplasty in a patient with renal artery stent subacute thrombosis
Cathet Cardiovasc Diagn
(1998)- et al.
Endovascular aneurysm treatmenta proven therapy
Neurol Res
(2002) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable anginathe CAPTURE Study
Lancet
(1997)- et al.
Use of abciximab for mediation of thromboembolic complications of endovascular therapy
AJNR Am J Neuroradiol
(2001) - et al.
Local intraarterial fibrinolysis of thromboemboli occurring during endovascular treatment of intracerebral aneurysma comparison of anatomic results and clinical outcome
AJNR Am J Neuroradiol
(1998) - et al.
Postprocedure ischemic events after treatment of intracranial aneurysms with Guglielmi detachable coils
J Neurosurg
(2002) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
N Engl J Med
(1994)
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
N Engl J Med
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II studya randomized controlled trial. Prolyse in acute cerebral thromboembolism
JAMA
Use of anti-GP IIb-IIIa in acute thrombosis after intracoronary stent implantation
Cathet Cardiovasc Diagn
Abciximab bolus injection does not reduce cerebral ischemic complications of elective carotid artery stentinga randomized study
Stroke
Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stentinga safe and effective adjunctive therapy
Stroke
Intraarterial thrombolysis for thromboemboli associated with endovascular aneurysm coiling
AJNR Am J Neuroradiol
Cited by (15)
Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor
2012, Molecular TherapyCitation Excerpt :However, this is the first description of an antiplatelet agent that can be neutralized rapidly and effectively by administration of an antidote molecule in vivo. Parenteral platelet inhibitors are used extensively by interventional cardiologists and radiologists and are now being used by neurosurgeons to aid in the surgical management of stroke and stent-assisted coiling of aneurysms.17,18,19,20,21,22 Both interventionalists and surgeons across vascular specialties are enthusiastic to use these types of drugs more extensively but are reluctant to do so because of concern for bleeding complications.
Anticoagulant and antiplatelet drugs in endovascular neurosurgery
2021, Craniospinal Vascular Diseases and Endovascular NeurosurgeryAnticoagulant and antiplatelet drugs in endovascular neurosurgery
2020, Legal Actions for Future GenerationsIntra-arterial versus intravenous abciximab therapy for thromboembolic complications of neuroendovascular procedures: Case review and meta-analysis
2017, Journal of NeuroInterventional Surgery
- ☆
Disclosure: Dr. Hopkins receives research support from and is a consultant for Boston Scientific and Cordis; in addition, he has a financial interest in Boston Scientific.